Lomustine
- Generic Name
- Lomustine
- Brand Names
- Ceenu, Gleostine
- Drug Type
- Small Molecule
- Chemical Formula
- C9H16ClN3O2
- CAS Number
- 13010-47-4
- Unique Ingredient Identifier
- 7BRF0Z81KG
- Background
An alkylating agent of value against both hematologic malignancies and solid tumors.
- Indication
For the treatment of primary and metastatic brain tumors as a component of combination chemotherapy in addition to appropriate surgical and/or radiotherapeutic procedures. Also used in combination with other agents as secondary therapy for the treatment of refractory or relapsed Hodgkin's disease.
- Associated Conditions
- Metastatic Brain Tumors, Primary Brain Neoplasm, Refractory Hodgkin Lymphoma
- Associated Therapies
- -
Combination Chemotherapy in Treating Children With Progressive Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 428
- Registration Number
- NCT00002944
- Locations
- ๐บ๐ธ
Nationwide Children's Hospital, Columbus, Ohio, United States
๐บ๐ธSt. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
๐บ๐ธJonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 370
- Registration Number
- NCT00003375
Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 299
- Registration Number
- NCT00002569
- Locations
- ๐บ๐ธ
Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States
๐บ๐ธJonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
๐บ๐ธLouisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 32
- Registration Number
- NCT00006024
- Locations
- ๐บ๐ธ
Children's Hospital of Columbus, Columbus, Ohio, United States
๐บ๐ธCleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
๐จ๐ญSwiss Pediatric Oncology Group Lausanne, Lausanne, Switzerland
Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT00049439
- Locations
- ๐บ๐ฌ
Uganda Cancer Institute, Kampala, Uganda
๐บ๐ธHerbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States
๐ฐ๐ชUniversity of Nairobi College of Health Sciences, Nairobi, Kenya
Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Riverside Haematology Group
- Target Recruit Count
- 660
- Registration Number
- NCT00003603
- Locations
- ๐ฌ๐ง
Hammersmith Hospital, London, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.